Greylock portfolio AI companies

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and has made significant advancements in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain — and continues to progress clinical and research programs in these diseases. We also have a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where we have deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Our global headquarters is in Boston, and we have research and development (R&D) sites and commercial offices worldwide.Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. We have also earned a spot on TIME Most Influential Companies, TIME Best Inventions, and Fast Company Most Innovative Companies lists. Our research and medicines have received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the Prix Galien, the Scrip Award and the Breakthrough Prize awards.Read our community guidelines: https://www.vrtx.com/vertexs-community-guidelines/

• Post-IPO debt
• 6.5k employees
• Founded 1989

Snorkel AI is the frontier AI data lab, helping teams build the data and environments behind high-performing frontier and agentic AI. We combine platform technology with research-driven data development to create datasets, benchmarks, evals, and custom solutions for real-world AI systems. Founded out of the Stanford AI Lab in 2019, Snorkel works with leading AI labs and enterprises to move from better data to better outcomes. Snorkel led the development of Senior SWE-Bench and launched Open Benchmarks Grants with a $3 million commitment to support open-source datasets, benchmarks, and evaluation research. Supported projects include Agents’ Last Exam, OSWorld 2.0, Terminal-Bench, Continual Learning Bench, and SlopCode Bench. Learn more at snorkel.ai or follow @SnorkelAI.

• Series unknown
• 1.3k employees
• Founded 2019

AI-powered drug discovery platform for rapid molecule screening and testing, from target identification to lab validation. Automating biotech R&D.About Optic Optic started as an AI research team developing high-performance similarity search algorithms. Today our proprietary AI-technology is powering products in multiple industries from blockchain to biotech.

• Seed
• 283 employees
• Founded 2021

AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.

• Post-IPO equity
• 204 employees
• Founded 2001

Disrupting drug development.

• Seed
• 32 employees
• Founded 2025